This study compared the efficacy of first-line Afatinib and Osimertinib in patients with advanced NSCLC harboring EGFR exon 19 deletions without baseline CNS metastases, focusing on real-world outcomes under Taiwan’s NHI reimbursement regulations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.